Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines

V. Santini; P. E. Alessandrino; E. Angelucci; G. Barosi; A. Billio; Atto Billio; M. Di Maio; C. Finelli; Franco Locatelli; M. Marchetti; E. Morra; P. Musto; G. Visani; S. Tura

doi:10.1016/j.leukres.2010.01.018

Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines

V. Santini, P. E. Alessandrino, E. Angelucci, G. Barosi, A. Billio, Atto Billio, M. Di Maio, C. Finelli, Franco Locatelli, M. Marchetti, E. Morra, P. Musto, G. Visani, S. Tura

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

Since 2002, date of publication of the previous Italian Society of Haematology (SIE) practice guidelines for management of myelodysplastic syndromes (MDS), novel disease-modifying treatments have been introduced and the SIE commissioned an update.After a comprehensive review of the medical literature published since January 2001, the Expert Panel formulated recommendations for the management of adult and paediatric MDS, graded according to the available evidence.The major updates are: first-line hypomethylating agents in patients with INT2-high-risk disease; controlled use of first-line lenalidomide in low-INT1 risk transfusion-dependent patients with 5q deletion; deferasirox in low-INT1 patients with a relevant transfusional load; first-line high-dose ESA in low-INT1 patients with Hb < 10 g/dl and endogenous EPO < 500 U/l; allogeneic HSCT first-line therapy for INT2- and high-risk patients <65 years without severe co morbidities. (C) 2010 Elsevier Ltd. All rights reserved.

Lingua originale	English
pagine (da-a)	1576-1588
Numero di pagine	13
Rivista	Leukemia Research
Volume	34
DOI	https://doi.org/10.1016/j.leukres.2010.01.018
Stato di pubblicazione	Pubblicato - 2010

Keywords

Myelodysplastic syndromes
Clinical practice guidelines
HSCT
Immunosuppressive therapy
del5q
Hematopoietic growth factors
Immunomodulating agents
Iron chelation
Hypomethylating therapy

Accesso al documento

10.1016/j.leukres.2010.01.018

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Santini, V., Alessandrino, P. E., Angelucci, E., Barosi, G., Billio, A., Billio, A., Di Maio, M., Finelli, C., Locatelli, F., Marchetti, M., Morra, E., Musto, P., Visani, G., & Tura, S. (2010). Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leukemia Research, 34, 1576-1588. https://doi.org/10.1016/j.leukres.2010.01.018

@article{456274692ddc43da8d4bb1500ad7662a,

title = "Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines",

abstract = "Since 2002, date of publication of the previous Italian Society of Haematology (SIE) practice guidelines for management of myelodysplastic syndromes (MDS), novel disease-modifying treatments have been introduced and the SIE commissioned an update.After a comprehensive review of the medical literature published since January 2001, the Expert Panel formulated recommendations for the management of adult and paediatric MDS, graded according to the available evidence.The major updates are: first-line hypomethylating agents in patients with INT2-high-risk disease; controlled use of first-line lenalidomide in low-INT1 risk transfusion-dependent patients with 5q deletion; deferasirox in low-INT1 patients with a relevant transfusional load; first-line high-dose ESA in low-INT1 patients with Hb < 10 g/dl and endogenous EPO < 500 U/l; allogeneic HSCT first-line therapy for INT2- and high-risk patients <65 years without severe co morbidities. (C) 2010 Elsevier Ltd. All rights reserved.",

keywords = "Myelodysplastic syndromes, Clinical practice guidelines, HSCT, Immunosuppressive therapy, del5q, Hematopoietic growth factors, Immunomodulating agents, Iron chelation, Hypomethylating therapy, Myelodysplastic syndromes, Clinical practice guidelines, HSCT, Immunosuppressive therapy, del5q, Hematopoietic growth factors, Immunomodulating agents, Iron chelation, Hypomethylating therapy",

author = "V. Santini and Alessandrino, {P. E.} and E. Angelucci and G. Barosi and A. Billio and Atto Billio and {Di Maio}, M. and C. Finelli and Franco Locatelli and M. Marchetti and E. Morra and P. Musto and G. Visani and S. Tura",

year = "2010",

doi = "10.1016/j.leukres.2010.01.018",

language = "English",

volume = "34",

pages = "1576--1588",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines

AU - Santini, V.

AU - Alessandrino, P. E.

AU - Angelucci, E.

AU - Barosi, G.

AU - Billio, A.

AU - Billio, Atto

AU - Di Maio, M.

AU - Finelli, C.

AU - Locatelli, Franco

AU - Marchetti, M.

AU - Morra, E.

AU - Musto, P.

AU - Visani, G.

AU - Tura, S.

PY - 2010

Y1 - 2010

N2 - Since 2002, date of publication of the previous Italian Society of Haematology (SIE) practice guidelines for management of myelodysplastic syndromes (MDS), novel disease-modifying treatments have been introduced and the SIE commissioned an update.After a comprehensive review of the medical literature published since January 2001, the Expert Panel formulated recommendations for the management of adult and paediatric MDS, graded according to the available evidence.The major updates are: first-line hypomethylating agents in patients with INT2-high-risk disease; controlled use of first-line lenalidomide in low-INT1 risk transfusion-dependent patients with 5q deletion; deferasirox in low-INT1 patients with a relevant transfusional load; first-line high-dose ESA in low-INT1 patients with Hb < 10 g/dl and endogenous EPO < 500 U/l; allogeneic HSCT first-line therapy for INT2- and high-risk patients <65 years without severe co morbidities. (C) 2010 Elsevier Ltd. All rights reserved.

AB - Since 2002, date of publication of the previous Italian Society of Haematology (SIE) practice guidelines for management of myelodysplastic syndromes (MDS), novel disease-modifying treatments have been introduced and the SIE commissioned an update.After a comprehensive review of the medical literature published since January 2001, the Expert Panel formulated recommendations for the management of adult and paediatric MDS, graded according to the available evidence.The major updates are: first-line hypomethylating agents in patients with INT2-high-risk disease; controlled use of first-line lenalidomide in low-INT1 risk transfusion-dependent patients with 5q deletion; deferasirox in low-INT1 patients with a relevant transfusional load; first-line high-dose ESA in low-INT1 patients with Hb < 10 g/dl and endogenous EPO < 500 U/l; allogeneic HSCT first-line therapy for INT2- and high-risk patients <65 years without severe co morbidities. (C) 2010 Elsevier Ltd. All rights reserved.

KW - Myelodysplastic syndromes

KW - Clinical practice guidelines

KW - HSCT

KW - Immunosuppressive therapy

KW - del5q

KW - Hematopoietic growth factors

KW - Immunomodulating agents

KW - Iron chelation

KW - Hypomethylating therapy

KW - Myelodysplastic syndromes

KW - Clinical practice guidelines

KW - HSCT

KW - Immunosuppressive therapy

KW - del5q

KW - Hematopoietic growth factors

KW - Immunomodulating agents

KW - Iron chelation

KW - Hypomethylating therapy

UR - http://hdl.handle.net/10807/250315

U2 - 10.1016/j.leukres.2010.01.018

DO - 10.1016/j.leukres.2010.01.018

M3 - Article

SN - 0145-2126

VL - 34

SP - 1576

EP - 1588

JO - Leukemia Research

JF - Leukemia Research

ER -

Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo